Anti-LOX-1 Antibody MEDI6570 for Plaque Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atherosclerosis primarily focus on lipid levels, but there is a need for therapies that address vascular inflammation and plaque stability to reduce acute coronary events, as existing methods fail to effectively inhibit LOX-1 mediated vascular dysfunction and plaque progression.
Innovation Solution
A LOX-1 binding protein, such as MEDI6570, an anti-LOX1 antibody with reduced effector function, is administered to inhibit LOX-1 activity, reducing vascular inflammation, stabilizing plaques, and decreasing non-calcified coronary plaque volume by targeting pro-inflammatory pathways and ROS production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard of care treatments (statins, platelet inhibitors, anti-hypertensives) are used, then cardiovascular mortality is reduced, but a large number of patients still suffer from major adverse cardiovascular events due to unaddressed vascular inflammation and plaque instability
Solution Approach 1:
The patent applies universality by developing a therapeutic approach that simultaneously addresses multiple pathological mechanisms in atherosclerosis. The treatment combines lipid-lowering effects with anti-inflammatory actions targeting LOX-1, vascular protection, and plaque stabilization, allowing a single therapeutic strategy to combat multiple disease processes that standard care treatments address separately
2Object-affected harmful factors
If LOX-1 binding protein is administered to inhibit LOX-1 activity, then vascular inflammation is reduced and plaque stability is improved, but new therapeutic mechanisms must be validated for clinical efficacy
Solution Approach 1:
The patent employs the intermediary principle by using a LOX-1 binding protein as a mediator to block the interaction between LOX-1 and its ligands (ox-LDL, AGEs, cytokines). This binding protein acts as an intermediary that prevents the harmful signaling cascade initiated by LOX-1 activation, thereby reducing vascular inflammation and protecting endothelial function without directly interfering with other physiological processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
MEDI6570 effectively reduces non-calcified coronary plaque volume, stabilizes plaques, and decreases the risk of acute coronary events by inhibiting LOX-1 activity, demonstrating therapeutic benefits in treating atherosclerosis and related disorders.
Implementation Method 1
LOX-1 is a multiligand receptor that binds to many compounds including, but not limited to, oxidized LDL (ox-LDL), activated platelets, cytokines and advanced glycation end products (AGEs)
Implementation Method 2
LOX-1 activation by ox-LDL triggers a cascade of intracellular signaling that leads to foam cell formation, endothelial dysfunction, apoptosis, vascular SMC proliferation, collagen degradation, reactive oxygen species generation, vascular inflammation and platelet activation
Data Source
AI summary
The present invention relates to methods for treating vascular inflammation, atherosclerosis and related disorders in a subject using a lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) binding protein, such as an anti-LOX-1 antibody or a LOX-1 binding fragment thereof. Also disclosed are dosage regimens for use in treating LOX-1 related disorders.